NCT01604057View on ClinicalTrials.gov

Study to Evaluate Effect of Intranasal Teriparatide on Serum P1NP, a Biomarker of Bone Formation, in Postmenopausal Women With Low Bone Mass

PHASE2UnknownINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
OsteoporosisOsteopenia
Interventions
DRUG

ZT-034 Low Dose Nasal Spray

Nasal Spray

DRUG

ZT-034 Mid Dose Nasal Spray

Nasal Spray

DRUG

ZT-034 High Dose Nasal Spray

Nasal Spray

DRUG

Teriparatide

20 mcg subcutaneous daily

DRUG

Placebo

Nasal Spray

Sponsors
All Listed Sponsors
lead

Azelon Pharmaceuticals

INDUSTRY

NCT01604057 - Study to Evaluate Effect of Intranasal Teriparatide on Serum P1NP, a Biomarker of Bone Formation, in Postmenopausal Women With Low Bone Mass | Biotech Hunter | Biotech Hunter